047 - PHASE 2 KEYNOTE-667 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (Chl) AND SLOW EARLY RESPONSE (SER) TO FRONTLINE CHEMOTHERAPY (CHEMO).

Authors :: Vinti, L.
Daw, Stephen
Alvarez, C.
Fagioli, F.
Beishuizen, A.
Michel, G.
Moleti, M.
Cepelova, M.
Thorwarth, A.
Rigaud, C.
de Sabando, D.
Parker, J.
Zhu, Y.
Pillai, P.
Nahar, A.
Mauz-Koerholz, C.
Source :: Leukemia Research. 2022 Supplement, Vol. 121, pS33-S34. 2p.
Publication Year :: 2022

Subjects :: *YOUNG adults
*HODGKIN'S disease
*PEMBROLIZUMAB
*CANCER chemotherapy
*DIAGNOSIS

Full Text Access

Tools